The Effect of Lowering Blood Pressure by Magnesium Supplementation in Diabetic Hypertensive Adults With Low Serum Magnesium Levels: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

J Hum Hypertens. 2009 Apr;23(4):245-51. doi: 10.1038/jhh.2008.129. Epub 2008 Nov 20.

Abstract

To test the blood pressure (BP)-lowering effect of oral magnesium supplementation (that is, magnesium chloride (MgCl(2)) solution) in diabetic hypertensive adults with hypomagnesaemia not on diuretic treatment but receiving concurrent captopril, we conducted a double-blind, placebo-controlled trial. Eighty-two subjects between 40 and 75 years of age were randomly enrolled. Over 4 months, subjects in the intervention group received 2.5 g of MgCl(2) (50 ml of a solution containing 50 g of MgCl(2) per 1000 ml of solution) equivalent to 450 mg of elemental magnesium, and control subjects inert placebo. The primary trial end point was a reduction in systolic (SBP) and diastolic (DBP) blood pressure. Complete follow-up was achieved for 79 of the 82 randomized subjects. SBP (-20.4+/-15.9 versus -4.7 +/- 12.7 mm Hg, P=0.03) and DBP (-8.7+/-16.3 versus -1.2+/-12.6 mm Hg, P=0.02) showed significant decreases, and high-density lipoprotein-cholesterol (0.1+/-0.6 versus -0.1+/-0.7 mmol l(-1), P=0.04) a significant increase in the magnesium group compared to the placebo group. The adjusted odds ratio between serum magnesium and BP was 2.8 (95%CI: 1.4-6.9). Oral magnesium supplementation with MgCl(2) significantly reduces SBP and DBP in diabetic hypertensive adults with hypomagnesaemia.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Diabetic Angiopathies / blood*
  • Diabetic Angiopathies / drug therapy*
  • Double-Blind Method
  • Female
  • Humans
  • Hypertension / blood*
  • Hypertension / drug therapy*
  • Magnesium Chloride / blood*
  • Magnesium Chloride / therapeutic use*
  • Male
  • Middle Aged

Substances

  • Magnesium Chloride